Theory Paper IIIDrNB Cardiology – Theory Notes
BIORESORBABLE SCAFFOLDS (BRS): THE 2026 RESURRECTION AND CURRENT STATUS
ITHE RATIONALE: “LEAVE NOTHING BEHIND”
- The Core Concept: A Bioresorbable Scaffold (BRS) provides transient mechanical radial support and antiproliferative drug elution for 3 to 12 months during the acute phase of vessel recoil and neointimal healing, and then completely resorbs—leaving the native coronary artery uncaged.
- Theoretical Long-Term Benefits:
- Restoration of Physiological Vasomotion: Uncages the vessel to restore cyclic pulsatility, adaptive shear-stress remodeling, and endothelial vasomotion.
- Preservation of Future Revascularization Options: Avoids a permanent “full metal jacket,” preserving distal anastomotic targets for future CABG and eliminating permanent side-branch jailing.
- Non-Invasive Imaging Compatibility: Eliminates metallic blooming artifacts on follow-up Coronary CT Angiography (CCTA).
IIFIRST-GENERATION FAILURE: LESSONS FROM ABSORB BVS
- Clinical Failure (ABSORB II, III, and AIDA Trials): The first-generation Absorb Bioresorbable Vascular Scaffold—constructed from poly-L-lactic acid (PLLA) eluting everolimus—was withdrawn globally in 2017 after randomized trials and meta-analyses demonstrated higher Target Lesion Failure (TLF) and a 2- to 3-fold higher rate of definite/probable Device Thrombosis (both early and very late, between 1 and 3 years) compared with thin-strut metallic everolimus-eluting stents (Xience).
- Three Root Causes of First-Generation Failure:
- Thick, Wide Struts (157 micrometers): Nearly double the thickness of contemporary metallic DES (60 to 80 micrometers), causing endothelial shear-stress disturbance, platelet activation, delayed endothelialization, and severe lumen loss when implanted in small vessels (reference diameter less than 2.25 to 2.50 mm).
- Suboptimal Implantation Technique: Early trials implanted scaffolds without routine 1:1 pre-dilation, intravascular imaging sizing, or high-pressure post-dilation.
- Intraluminal Scaffold Dismantling: During slow hydrolytic degradation of PLLA (taking 36 to 42 months), loss of structural integrity caused malapposed or discontinuous polymer struts to prolapse into the vessel lumen, triggering very late scaffold thrombosis.
IIISECOND- AND THIRD-GENERATION ADVANCES
- Thin-Strut Polymeric Scaffolds (Sub-100 Micrometers): Second-generation PLLA scaffolds—such as the Indian-engineered MeRes100 (sirolimus-eluting PLLA scaffold with 100-micrometer strut thickness and hybrid closed/open cells, resorbing in 24 to 36 months) and Fantom (desaminotyrosine polycarbonate, 125 micrometers)—markedly reduce flow separation and thrombogenicity.
- Resorbable Magnesium Scaffolds (Magmaris to Freesolve [DREAMS 3G]):
- Magmaris (DREAMS 2G): First-generation sirolimus-eluting magnesium scaffold (150-micrometer struts; 95 percent resorbed into amorphous calcium phosphate within 12 months).
- Freesolve (DREAMS 3G — BIOMAG-I Trial): Next-generation sirolimus-eluting BIOMAG magnesium alloy scaffold featuring thinner struts (99 to 147 micrometers), higher radial strength (minimizing late recoil), and complete 99.6 percent resorption at 12 months.
- Iron-Based Scaffolds: Ultrathin nitrided-iron bioresorbable scaffolds (IBS, 53-micrometer struts) provide metallic DES-like radial strength and trackability.
| Scaffold Generation & Name | Backbone Material | Strut Thickness | Complete Resorption Time | Key Clinical Trial / Registry Evidence |
|---|---|---|---|---|
| Absorb BVS (1st Gen — Withdrawn) | Poly-L-lactic acid (PLLA) | 157 um | 36–42 months | ABSORB III & AIDA: 2–3x higher scaffold thrombosis vs. Xience (ESC Class III) |
| MeRes100 (2nd Gen Polymer) | Sirolimus-eluting PLLA | 100 um | 24–36 months | MeRes-1 & MeRes-1 Extend: 0% scaffold thrombosis and 1.87% MACE at 3 years |
| Magmaris / DREAMS 2G (Metal) | Sirolimus-eluting Magnesium | 150 um | ~12 months (95%) | BIOSOLVE-IV Registry: Low scaffold thrombosis (0.5–0.7%) in simple lesions |
| Freesolve / DREAMS 3G (3rd Gen Metal) | Sirolimus-eluting BIOMAG Magnesium | 99–147 um | 12 months (99.6%) | BIOMAG-I Trial (2023/2024): Low late lumen loss and no scaffold thrombosis at 12 months |
IVTHE MANDATORY “PSP” IMPLANTATION PROTOCOL
- Why PSP is Essential (ABSORB IV & Pooled PSP Analyses): Post-hoc analyses and the ABSORB IV Trial demonstrated that strict adherence to the PSP (Prepare, Size, Post-dilate) Protocol plus excluding small vessels (<2.25–2.50 mm) reduces scaffold thrombosis by up to 70 percent:
- P — Prepare the Lesion (Pre-Dilation): Aggressive predilation using a 1:1 vessel-sized non-compliant balloon (or scoring/cutting balloon); the scaffold must not be implanted unless full balloon expansion with less than 30 percent residual stenosis is achieved.
- S — Size Appropriately (Mandatory Intravascular Imaging): Reference vessel diameter must be measured between 2.50 mm and 3.75 mm (strictly avoiding vessels smaller than 2.50 mm), guided by OCT or IVUS rather than visual estimation.
- P — Post-Dilate at High Pressure: Mandatory post-dilation using a Non-Compliant (NC) balloon at 16 to 20+ atm sized up to 0.25 to 0.50 mm larger than the nominal scaffold diameter (never exceeding the maximum expansion limit of a polymeric scaffold to avoid strut fracture).
VCLINICAL EVIDENCE AND CURRENT GUIDELINE STATUS
- Current Guideline Stance (ESC Revascularization Guidelines): Following the failure of first-generation Absorb BVS, the ESC Guidelines assigned a Class III (Level C) recommendation against the routine clinical use of first-generation bioresorbable scaffolds outside of clinical studies.
- Contemporary Niche Indications (Investigational / Selected Use of Newer-Generation BRS):
- Lesion Profile: Discrete, de novo, non-ostial, non-calcified or mildly calcified lesions in vessels 2.50 to 3.75 mm in diameter (excluding left main, true bifurcations requiring two stents, chronic total occlusions, and saphenous vein grafts).
- Patient Profile: Selected young patients with single-vessel or long LAD disease (including “hybrid” PCI combining a proximal metallic DES with a mid/distal BRS or Drug-Coated Balloon to preserve the mid-LAD for future LIMA grafting), always performed under OCT or IVUS guidance and followed by at least 12 months of Dual Antiplatelet Therapy (DAPT).
Key references
- Ali ZA, Gao R, Kimura T, et al.: Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials, Circulation, 2018.
- Seth A, Onuma Y, Costa R, et al.: Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 extend study, EuroIntervention, 2019.
- Haude M, Wlodarczak A, van der Schaaf RJ, et al. (BIOMAG-I Investigators): Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicentre BIOMAG-I first-in-human study, eClinicalMedicine, 2023.
- Verheye S, Wlodarczak A, Montorsi P, et al. (BIOSOLVE-IV Investigators): Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry, EuroIntervention, 2020.
meritmedscript.comDr. Sidhartha Mullapudi
